Fingerprint
Dive into the research topics of 'Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study
Carlo Gambacorti-Passerini, Sergey Orlov, Li Zhang, Fadi Braiteh, Huiqiang Huang, Taito Esaki, Keizo Horibe, Jin Seok Ahn, Joseph T. Beck, William Jeffrey Edenfield, Yuankai Shi, Matthew Taylor, Kenji Tamura, Brian A. Van Tine, Shang Ju Wu, Jolanda Paolini, Paulina Selaru, Tae Min Kim
Research output: Contribution to journal › Article › peer-review
73
Scopus
citations